Simvastatin reduces CD40 expression in an experimental model of early arterialization of saphenous vein graft.

[1]  R. Lauro,et al.  Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients , 2005, Circulation.

[2]  R. Zhong,et al.  Relationship between expression of CD40-CD40 ligand system and serum cholesterol levels in patients with hypercholesterolemia. , 2004, Chinese medical journal.

[3]  P. Aukrust,et al.  Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation? , 2004, Journal of the American College of Cardiology.

[4]  N. Cheshire,et al.  Phenotypic and functional differences between human saphenous vein (HSVEC) and umbilical vein (HUVEC) endothelial cells. , 2004, Atherosclerosis.

[5]  T. Lüscher,et al.  Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. , 2003, Cardiovascular research.

[6]  G. Patti,et al.  Pressure distension stimulates the expression of endothelial adhesion molecules in the human saphenous vein graft. , 2003, The Annals of thoracic surgery.

[7]  J. Freedman.  CD40-CD40L and platelet function: beyond hemostasis. , 2003, Circulation research.

[8]  R. Callard,et al.  CD40 Is Constitutively Expressed on Platelets and Provides a Novel Mechanism for Platelet Activation , 2003, Circulation research.

[9]  C. Heeschen,et al.  Soluble CD40 ligand in acute coronary syndromes. , 2003, New England Journal of Medicine.

[10]  P. Libby,et al.  Oxidized Low-Density Lipoprotein Augments and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 and CD40L Expression in Human Vascular Cells , 2002, Circulation.

[11]  M. Hecker,et al.  3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase-Independent Inhibition of CD40 Expression by Atorvastatin in Human Endothelial Cells , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[12]  J. Shuhaiber,et al.  Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[13]  G. Davı̀,et al.  , Hypercholesterolemia : Effects of Statin Therapy Association Between Enhanced Soluble CD 40 L and Prothrombotic State in , 2002 .

[14]  H. Gold,et al.  Cardiopulmonary Bypass Induces Release of Soluble CD40 Ligand , 2002, Circulation.

[15]  W. Daniel,et al.  Upregulation of CD40 and CD40 Ligand (CD154) in Patients With Moderate Hypercholesterolemia , 2001, Circulation.

[16]  P. Libby,et al.  Soluble CD40L and Cardiovascular Risk in Women , 2001, Circulation.

[17]  S. Miller,et al.  Emerging mechanisms for secondary cardioprotective effects of statins. , 2001, Cardiovascular research.

[18]  P. Crean,et al.  Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. , 2001, The American journal of cardiology.

[19]  A. M. Lefer,et al.  Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. , 2001, Cardiovascular research.

[20]  D. M. Elnicki,et al.  Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. , 2000, The American journal of cardiology.

[21]  R. Phipps.  Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  F. Perticone,et al.  Nitric oxide modulation of neutrophil-endothelium interaction: difference between arterial and venous coronary bypass grafts. , 1998, Journal of the American College of Cardiology.

[23]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[24]  R. Reneman,et al.  Venous myogenic tone and its regulation through K+ channels depends on chronic intravascular pressure. , 1997, Circulation research.

[25]  P. Libby,et al.  Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? , 1997, Circulation research.

[26]  J. Powell,et al.  Development of an in vitro model to study the response of saphenous vein endothelium to pulsatile arterial flow and circumferential deformation. , 1997, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[27]  F. Ruschitzka,et al.  Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels. Implications for venous bypass graft failure. , 1997, Circulation.

[28]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[29]  W J Keon,et al.  Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. , 1996, Journal of the American College of Cardiology.

[30]  P. Kiener,et al.  Expression of functional CD40 by vascular endothelial cells , 1995, The Journal of experimental medicine.